You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奧翔藥業(603229.SZ):擬以3500萬元參投上海以康二期
格隆匯 03-07 15:36

格隆匯3月6日丨奧翔藥業(603229.SZ)公佈,為優化公司資金配置,提早發掘未來醫藥行業優質資產,公司於2022年3月7日與各合夥人簽署《上海以康二期股權投資合夥企業(有限合夥)合夥協議》,公司將作為有限合夥人認繳出資額人民幣3500萬元,占上海以康二期股權投資合夥企業(有限合夥)(“標的基金”)總認繳出資額的11.6667%。

上海以康二期股權投資合夥企業(有限合夥)聚焦生物技術、醫療器械和創新領域的股權投資及相關投資業務,公司本次投資標的基金,有利於公司藉助專業投資機構的團隊優勢及資源優勢,提早發掘未來醫藥行業優質資產,符合公司未來業務拓展和戰略發展的需求,有利於進一步提升公司的綜合競爭能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account